Find out why Dr. Rimm’s work suggests that a subset of cells that have lost beta-catenin expression may be associated with non-response. In this seminar recording from USCAP 2020, Dr. Rimm explains how you can benefit from exploratory analysis using AI-powered phenotyping.
Learn how his group used Visiopharm AI-based software to help them get meaningful results from next-gen imaging technologies like Fluidigm's IMC.
David has authored over 400 peer-reviewed papers and holds eight patents. His research lab group focuses on quantitative pathology using the AQUA® technology invented in his lab, and other quantitative methods, including Visiopharm´s phenotyping module.
His projects relate to predicting response to both targeted and immune- therapy in cancer and standardization of those assays for CLIA labs.